busulfan and Benign Neoplasms studies

Research Excerpts

Excerpt	Relevance	Reference
"Hepatic veno-occlusive disease (HVOD) is a frequent life-threatening toxicity in patients undergoing bone marrow transplantation (BMT) after the administration of a high-dose busulfan-containing regimen."	7.69	Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. ( Boland, I; Challine, D; Deroussent, A; Gouyette, A; Hartmann, O; Koscielny, S; Lemerle, J; Valteau-Couanet, D; Vassal, G, 1996)
"Risk factors for hepatic veno-occlusive disease (HVOD) were analysed in a population of 136 autografted children who received high-dose busulfan (BU) as part of a conditioning regimen."	7.68	Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. ( Benhamou, E; Brugieres, L; Hartmann, O; Lemerle, J; Méresse, V; Valteau-Couanet, D; Vassal, G, 1992)
" On the basis of the final models, we simulated two dosing schemes according to allometric BW and BSA showing that we estimated to include about 30% more patients into the proposed therapeutic area under the curve (AUC) range of 900 to 1,500 μM*min and could, furthermore, achieve a reduction in the AUC variability when dosed according to the labeled European Medicines Agency (EMA) dosing recommendation."	5.37	Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children. ( Bergstrand, M; Boos, J; Hempel, G; Karlsson, MO; Trame, MN, 2011)
"A new intravenous (IV) dosing of busulfan (Bu) based on body weight, designed to improve AUC targeting without TDM and dose-adjustment, was prospectively evaluated."	5.13	Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. ( Doz, F; Espérou, H; Galambrun, C; Gentet, JC; Mechinaud, F; Michel, G; Neven, B; Nguyen, L; Puozzo, C; Valteau-Couanet, D; Vassal, G; Zouabi, H, 2008)
"A strong relationship has been demonstrated between high systemic exposure to busulfan and the occurrence of hepatic veno-occlusive disease (HVOD) after a busulfan-cyclophosphamide regimen (BU CY)."	5.10	In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa). ( Boland, I; Bouligand, J; Deroussent, A; Hartmann, O; Kalifa, C; Valteau-Couanet, D; Vassal, G, 2003)
"Breast cancer survivors, those treated with procarbazine or other alkylating agents and those with a higher age at diagnosis are at highest risk of diminished ovarian function."	4.95	Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood and young adult cancer: A systematic review. ( Kaspers, GJ; Lambalk, CB; Overbeek, A; van den Berg, MH; van Dulmen-den Broeder, E; van Leeuwen, FE, 2017)
" In this report, we analyzed the outcome of 101 high-risk patients (70 hematologic and 31 nonhematologic malignancies) who received an HLA-identical sibling allo-SCT after RIC, including fludarabine, busulfan, and antithymocyte globulin (ATG)."	3.72	Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. ( Bay, JO; Bilger, K; Blaise, D; Chabannon, C; Choufi, B; Coso, D; Faucher, C; Maraninchi, D; Mohty, M; Stoppa, AM; Tournilhac, O; Vey, N; Viens, P, 2003)
"In this study we have used a standardised ATP-based tumour chemosensitivity assay (ATP-TCA) to measure the activity of gefitinib alone or in combination with different cytotoxic drugs (cisplatin, gemcitabine, oxaliplatin and treosulfan) against a variety of solid tumours (n = 86), including breast, colorectal, oesophageal and ovarian cancer, carcinoma of unknown primary site, cutaneous and uveal melanoma, non-small cell lung cancer (NSCLC) and sarcoma."	3.72	The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours. ( Cree, IA; Di Nicolantonio, F; Glaysher, S; Johnson, P; Knight, LA; Mercer, S; Sharma, S; Whitehouse, P, 2004)
"Hepatic veno-occlusive disease (HVOD) is a frequent life-threatening toxicity in patients undergoing bone marrow transplantation (BMT) after the administration of a high-dose busulfan-containing regimen."	3.69	Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. ( Boland, I; Challine, D; Deroussent, A; Gouyette, A; Hartmann, O; Koscielny, S; Lemerle, J; Valteau-Couanet, D; Vassal, G, 1996)
"Risk factors for hepatic veno-occlusive disease (HVOD) were analysed in a population of 136 autografted children who received high-dose busulfan (BU) as part of a conditioning regimen."	3.68	Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. ( Benhamou, E; Brugieres, L; Hartmann, O; Lemerle, J; Méresse, V; Valteau-Couanet, D; Vassal, G, 1992)
"In high-risk malignancy, low acute toxicity was followed by low TRM but it did not translate into increased survival."	2.78	Long-term follow-up of children conditioned with Treosulfan: German and Austrian experience. ( Bader, P; Beier, R; Ehlert, K; Eyrich, M; Greil, J; Gruhn, B; Holter, W; Hönig, M; Meisel, R; Müller, I; Nürnberger, W; Sauer, M; Schlegel, PG; Schulz, A; Stachel, KD; Suttorp, M; Sykora, KW; Urban, C; Wössmann, W; Zimmermann, M, 2013)
"The final pharmacokinetic parameter were the clearance (CL/F) = 0."	2.75	Population pharmacokinetic study of a test dose oral busulfan in Japanese adult patients undergoing hematopoietic stem cell transplantation. ( Hara, S; Jimi, S; Ogata, K; Sasaki, N; Takamatsu, Y; Tamura, K; Yukawa, E, 2010)
"Busulfan was combined with cyclophosphamide and melphalan (n=30), melphalan (n=27), and thiotepa (n=20)."	2.73	Elevated plasma ferritin and busulfan pharmacodynamics during high-dose chemotherapy regimens in children with malignant solid tumors. ( Benhamou, E; Bouligand, J; Drouard-Troalen, L; Grill, J; Hartmann, O; Le Maitre, A; Paci, A; Valteau-Couanet, D; Vassal, G, 2007)
"The objective of this study was to characterize the pharmacokinetics (PK) of intravenous busulfan in pediatric patients and provide dosing recommendations."	2.73	Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients. ( Booth, BP; Dagher, R; Fuller, D; Gobburu, JV; Griebel, D; Lennon, S; Mehta, M; Rahman, A; Sahajwalla, C, 2007)
" This IV form is expected to reduce the high pharmacokinetic variability exhibited with oral busulfan and as a result, to better target the plasma area under the curve (AUC)."	2.72	Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. ( Leger, F; Lennon, S; Nguyen, L; Puozzo, C, 2006)
"A Phase I dose escalation and pharmacokinetic study of the alkylating cytotoxic agent treosulfan was conducted to evaluate the maximum tolerated dose and the dose-limiting toxicities in patients with advanced malignancies rescued by autologous peripheral blood stem cell transplantation."	2.69	Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. ( Baumgart, J; Berdel, WE; Bojko, P; Bornhäuser, M; Casper, J; Ehninger, G; Freund, M; Harstrick, A; Hilger, RA; Josten, KM; Oberhoff, C; Scheulen, ME; Schindler, AE; Seeber, S; Wolf, HH, 2000)
" The terminal half-life of treosulfan was in the range of 1."	2.69	Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors. ( Baumgart, J; Eberhardt, W; Harstrick, A; Hilger, RA; Oberhoff, C; Scheulen, ME; Seeber, S; Skorzec, M, 1998)
"Drug-induced pulmonary disease is an infrequent, but clinically significant, toxic manifestation of antineoplastic drug therapy."	2.36	Pulmonary toxicity of antineoplastic drugs. ( Willson, JK, 1978)
"However, the risk for subsequent malignant neoplasms (SMN) remains a significant concern."	1.72	Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial. ( Albert, MH; Bader, P; Basu, O; Beier, R; Burkhardt, B; Classen, CF; Claviez, A; Corbacioglu, S; Deubzer, HE; Eichinger, A; Glogova, E; Greil, J; Gruhn, B; Güngör, T; Kafa, K; Kühl, JS; Lang, P; Lange, BS; Meisel, R; Müller, I; Peters, C; Poetschger, U; Sauer, MG; Schlegel, PG; Schulz, A; Stachel, D; Strahm, B; Wawer, A, 2022)
"The most common primary cancer was acute lymphoblastic leukemia (22 patients, 31."	1.56	Factors predicting endocrine late effects in childhood cancer survivors from a Japanese hospital. ( Kazukawa, I; Kihara, M; Minagawa, M; Mori, K; Shimazaki, S, 2020)
"Imprecise blood collections or cross-contamination of samples may lead to inaccurate drug concentration results and, subsequently, undesired low or high drug dosage calculations."	1.51	Pharmacokinetics: Unique Challenges in Blood Monitoring for Oncology Nurses. ( Andersson, BS; Gulbis, AM; Kalariya, N; Kawedia, JD; Myers, AL, 2019)
"Based on pharmacokinetic data for these five drugs, the results generated support the implementation of NHSE dose-banding tables."	1.48	Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence. ( Boddy, AV; Chatelut, E; Osborne, C; Paci, A; Veal, GJ; White-Koning, M, 2018)
" To solve this problem, we proposed a new dosing scheme, in which the amount of dose was adjusted dynamically according to the estimated precision of the AUC estimator."	1.39	A proposed dynamic dosing scheme to secure the target plasma drug concentrations based on the precision of the AUC estimate. ( Tsuruta, H; Wada, T, 2013)
"In solid tumors other than medulloblastoma, IV melphalan was used at 140 mg/m/d×1 day."	1.38	Once-daily intravenous busulfan for 47 pediatric patients undergoing autologous hematopoietic stem cell transplantation: a single center study. ( Díaz, MA; González-Vicent, M; Molina, B; Pérez, A, 2012)
"To evaluate the ability of a physiology-based pharmacokinetic (PBPK) model to predict the systemic drug exposure of high- and low-dose etoposide in children from a model developed with adult data."	1.38	Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children. ( Boos, J; Hempel, G; Kersting, G; Lippert, J; Willmann, S; Würthwein, G, 2012)
" On the basis of the final models, we simulated two dosing schemes according to allometric BW and BSA showing that we estimated to include about 30% more patients into the proposed therapeutic area under the curve (AUC) range of 900 to 1,500 μM*min and could, furthermore, achieve a reduction in the AUC variability when dosed according to the labeled European Medicines Agency (EMA) dosing recommendation."	1.37	Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children. ( Bergstrand, M; Boos, J; Hempel, G; Karlsson, MO; Trame, MN, 2011)
"We studied the pharmacokinetic (PK) profile of single daily dose i."	1.35	Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant. ( Chaudhury, S; Duerst, R; Jacobsohn, D; Kletzel, M; Schneiderman, J; Tse, WT, 2009)
"Cataracts affect a minority of long-term cancer survivors, but those who reported them were more likely to report that cancer had had a lasting effect on their overall health."	1.33	Cataracts among cancer survivors. ( Beck, M; Stava, C; Vassilopoulou-Sellin, R, 2005)
"Busulfan kinetics were best described by a one-compartment model (subroutine ADVAN 2 TRANS 2)."	1.32	Population pharmacokinetics of oral busulfan in children. ( Boos, J; Ehninger, G; Gruhn, B; Hempel, G; Jenke, A; Klingebiel, T; Mürdter, TE; Ritter, CA; Schiltmeyer, B; Schwab, M; Würthwein, G, 2003)
"Chronic low-dose busulfan therapy results in lung injury in 4-6% of patients after several years of treatment and once the cumulative dosage begins to approach 3g."	1.31	Idiopathic pneumonia syndrome following myeloablative chemotherapy and autologous transplantation. ( Bilgrami, SF; Bona, RD; Clive, JM; Edwards, RL; Feingold, JM; Kapur, D; McNally, D; Metersky, ML; Naqvi, BH; Raible, D; Tutschka, PJ, 2001)
"Busulfan 16 mg/kg was paired with cyclophosphamide 200 mg/kg (BuCY) or with etoposide 60 mg/kg (Bu-Vp)."	1.29	Busulfan-containing pre-transplant regimens for the treatment of solid tumors. ( Adler, SS; Feingold, JM; Ghalie, R; Kaizer, H; Korenblit, AD; Manson, S; Pruett, J; Reynolds, J; Valentino, LA, 1994)
"The two administration modes for VP-16, either diluted or undiluted, are bioequivalent in pharmacokinetic terms."	1.29	Pharmacokinetics of undiluted or diluted high-dose etoposide with or without busulfan administered to patients with hematologic malignancies. ( Bewermeier, P; Hossfeld, DK; Krüger, W; Mross, K; Stockschläder, M; Zander, A, 1994)
"Twenty-three patients developed a malignancy 1."	1.29	Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. ( Deeg, HJ; Devergie, A; Gluckman, E; Henry-Amar, M; Schoch, G; Socié, G; Storb, R; Sullivan, KM; Witherspoon, RP, 1996)
"Busulfan was given p."	1.28	Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. ( Benhamou, E; Brugières, L; Challine, D; Deroussent, A; Gouyette, A; Hartmann, O; Kalifa, C; Lemerle, J; Valteau-Couanet, D; Vassal, G, 1990)
" The mean elimination half-life was 2."	1.28	Pharmacokinetics of high-dose busulfan in children. ( Gouyette, A; Hartmann, O; Lemerle, J; Pico, JL; Vassal, G, 1989)

Research

Studies (185)

Authors

Clinical Trials (2)

Trial Overview

Trial Outcomes

Percentage of Participants Alive at 1 Year After Transplant

Percentage of Patients Alive at the End of the Trial

Timeframe	Studies, this research(%)	All Research%
pre-1990	105 (56.76)	18.7374
1990's	22 (11.89)	18.2507
2000's	28 (15.14)	29.6817
2010's	21 (11.35)	24.3611
2020's	9 (4.86)	2.80

Authors	Studies
Lin, R	1
Elf, S	1
Shan, C	1
Kang, HB	1
Ji, Q	1
Zhou, L	1
Hitosugi, T	1
Zhang, L	1
Zhang, S	1
Seo, JH	1
Xie, J	1
Tucker, M	1
Gu, TL	1
Sudderth, J	1
Jiang, L	1
Mitsche, M	1
DeBerardinis, RJ	1
Wu, S	1
Li, Y	1
Mao, H	1
Chen, PR	1
Wang, D	1
Chen, GZ	1
Hurwitz, SJ	1
Lonial, S	1
Arellano, ML	1
Khoury, HJ	1
Khuri, FR	1
Lee, BH	1
Lei, Q	1
Brat, DJ	1
Ye, K	1
Boggon, TJ	1
He, C	1
Kang, S	1
Fan, J	1
Chen, J	1
Nunez, L	1
Abedin, T	1
Naqvi, S	1
Shen, H	1
Chaudhry, A	1
Bellerby, S	1
Savoie, L	1
Daly, A	1
Shafey, M	1
Duggan, P	1
Storek, J	1
Jamani, K	1
Eichinger, A	1
Poetschger, U	1
Glogova, E	1
Bader, P	2
Basu, O	1
Beier, R	2
Burkhardt, B	1
Classen, CF	1
Claviez, A	1
Corbacioglu, S	1
Deubzer, HE	1
Greil, J	2
Gruhn, B	3
Güngör, T	1
Kafa, K	1
Kühl, JS	1
Lang, P	1
Lange, BS	1
Meisel, R	2
Müller, I	2
Sauer, MG	1
Schlegel, PG	2
Schulz, A	2
Stachel, D	1
Strahm, B	1
Wawer, A	1
Peters, C	1
Albert, MH	1
Tang, Y	1
Zhang, Z	1
Liu, S	1
Yao, Y	1
Pan, T	1
Qi, J	1
Kang, H	1
Liu, Y	1
Cai, C	1
Zhou, M	1
He, X	1
Hu, X	1
Ma, X	1
Wu, D	1
Han, Y	1
Silva, AMPSD	1
Barbosa, LC	1
Marques, LMA	1
Carreira, LY	1
Fonseca, FMCD	1
Lima, APC	1
Sodré, JJM	1
Pignati, LT	1
Araújo, OR	1
Silva, DCBD	1
Carlesse, FAMC	1
Zheng, X	1
Gao, H	1
Lu, N	1
Wang, M	1
Zhang, H	1
Zheng, Y	1
Shen, B	1
Cao, Y	1
Chen, X	1
Zhai, W	1
Wei, J	1
Yang, D	1
Zhang, R	1
Pang, A	1
Feng, S	1
Jiang, E	1
Han, M	1
Rix, A	1
Drude, NI	1
Mrugalla, A	1
Baskaya, F	1
Pak, KY	1
Gray, B	1
Kaiser, HJ	1
Tolba, RH	1
Fiegle, E	1
Lederle, W	1
Mottaghy, FM	1
Kiessling, F	1
Levêque, D	1
Becker, G	1
Shimazaki, S	1
Kazukawa, I	1
Mori, K	1
Kihara, M	1
Minagawa, M	1
Wang, L	2
Fan, X	1
Tang, W	1
Hu, J	1
Battipaglia, G	1
Mauff, K	1
Wendel, L	1
Angelucci, E	1
Mohty, M	3
Arcese, W	1
Santarone, S	1
Rubio, MT	1
Kroger, N	1
Fox, ML	1
Blaise, D	4
Iori, AP	1
Fanin, R	1
Chalandon, Y	1
Pioltelli, P	1
Marotta, G	1
Chiusolo, P	1
Sever, M	1
Solano, C	1
Contentin, N	1
de Wreede, LC	1
Czerw, T	1
Hernandez-Boluda, JC	1
Hayden, P	1
McLornan, D	1
Yakoub-Agha, I	1
White-Koning, M	1
Osborne, C	1
Paci, A	2
Boddy, AV	1
Chatelut, E	1
Veal, GJ	1
Ruyssinck, L	1
Toulouse, K	1
Bordon Cueto de Braem, V	1
Cauwels, R	1
Dhooge, C	1
Patel, PR	1
Senyuk, V	1
Rodriguez, NS	1
Oh, AL	1
Bonetti, E	1
Mahmud, D	1
Barosi, G	1
Mahmud, N	1
Rondelli, D	1
Kawedia, JD	1
Kalariya, N	1
Gulbis, AM	1
Andersson, BS	1
Myers, AL	1
Tsuruta, H	1
Wada, T	1
Wilhelmsson, M	1
Vatanen, A	1
Borgström, B	1
Gustafsson, B	1
Taskinen, M	1
Saarinen-Pihkala, UM	1
Winiarski, J	1
Jahnukainen, K	1
Abedin, S	1
Peres, E	1
Levine, JE	1
Choi, S	1
Yanik, G	1
Couriel, DR	1
Watanabe, E	1
Nishikawa, T	1
Ikawa, K	1
Yamaguchi, H	1
Abematsu, T	1
Nakagawa, S	1
Kurauchi, K	1
Kodama, Y	1
Tanabe, T	1
Shinkoda, Y	1
Matsumoto, K	1
Okamoto, Y	1
Takeda, Y	1
Kawano, Y	1
Overbeek, A	1
van den Berg, MH	1
van Leeuwen, FE	1
Kaspers, GJ	1
Lambalk, CB	1
van Dulmen-den Broeder, E	1
Tse, WT	1
Duerst, R	2
Schneiderman, J	1
Chaudhury, S	1
Jacobsohn, D	2
Kletzel, M	2
Takamatsu, Y	1
Sasaki, N	1
Ogata, K	1
Yukawa, E	1
Jimi, S	1
Hara, S	1
Tamura, K	1
Wang, Y	1
Scheiber, MN	1
Neumann, C	1
Calin, GA	1
Zhou, D	1
Miteva, M	1
Misciali, C	1
Fanti, PA	1
Vincenzi, C	1
Romanelli, P	1
Tosti, A	1
Cooper, AJ	1
Pinto, JT	1
Callery, PS	1
Kersting, G	1
Willmann, S	1
Würthwein, G	2
Lippert, J	1
Boos, J	3
Hempel, G	3
Geyer, MB	1
Jacobson, JS	1
Freedman, J	1
George, D	1
Moore, V	1
van de Ven, C	1
Satwani, P	1
Bhatia, M	1
Garvin, JH	1
Bradley, MB	1
Harrison, L	1
Morris, E	1
Della-Latta, P	1
Schwartz, J	1
Baxter-Lowe, LA	1
Cairo, MS	1
Trame, MN	1
Bergstrand, M	1
Karlsson, MO	1
González-Vicent, M	1
Molina, B	1
Pérez, A	1
Díaz, MA	2
Hönig, M	1
Eyrich, M	1
Holter, W	1
Stachel, KD	1
Ehlert, K	1
Nürnberger, W	1
Wössmann, W	1
Urban, C	1
Suttorp, M	1
Sauer, M	1
Zimmermann, M	1
Sykora, KW	1
Castagna, L	1
Tsukagoshi, S	1
Maeda, Y	1
Sasaki, T	1
Bay, JO	2
Faucher, C	3
Choufi, B	2
Bilger, K	2
Tournilhac, O	1
Vey, N	1
Stoppa, AM	1
Coso, D	1
Chabannon, C	2
Viens, P	2
Maraninchi, D	2
Ruiz-Argüelles, GJ	1
López-Martínez, B	1
Gómez-Rangel, D	1
Estrada, E	1
Marín-López, A	1
Bravo-Hernández, G	1
Manuel Hernández, J	1
Schiltmeyer, B	1
Klingebiel, T	1
Schwab, M	1
Mürdter, TE	1
Ritter, CA	1
Jenke, A	2
Ehninger, G	4
Ohashi, K	2
Sanaka, M	1
Tu, Y	1
Egawa, N	1
Funata, N	1
Okuyama, Y	1
Hiruma, K	1
Tanaka, Y	1
Mori, S	1
Akiyama, H	1
Sakamaki, H	1
Michallet, M	1
Boiron, JM	2
Cahn, JY	1
Gratecos, N	1
Sotto, JJ	1
François, S	1
Fleury, J	1
Gravis, G	1
Viret, F	1
Braud, AC	1
Bardou, VJ	1
Shapira, MY	1
Or, R	1
Resnick, IB	1
Bitan, M	1
Ackerstein, A	1
Samuel, S	1
Elad, S	1
Zilberman, I	1
Miron, S	1
Slavin, S	1
KANO, K	1
TANAKA, T	1
HYMAN, GA	1
GELLHORN, A	1
PENG, CT	1
HADDOW, A	3
TIMMIS, GM	3
BROWN, SS	1
MILLER, E	1
BIERMAN, HR	2
KELLY, KH	1
KNUDSON, AG	1
MAEKAWA, T	1
MOORE, JG	1
BRANDKAMP, WW	1
BURNES, WL	1
BRAMBILLA, G	1
BALDINI, L	1
PITNEY, WR	1
BERENBAUM, MC	1
CALLEY, M	1
WHITE, FR	2
ANGUS, HB	1
GUNZ, FW	1
LEAKE, E	1
SMITH, WG	1
ELSON, LA	2
EVANS, AM	1
RIEKHOF, P	1
CHU, TH	1
WU, YI	1
DOCTOR, VM	1
DE BERGSAGEL, DE	1
SHULLENBERGER, CC	1
PICCINI, A	1
TARGETTI, M	1
WILTSHAW, E	1
BALGOZHINA, SZ	1
DUHAMEL, G	1
BOUSSER, J	1
GOLDENBERG, DM	1
SVOBODA, V	2
NIZET, A	1
DOGLIOTTI, GC	1
RITZ, ND	1
PURFAR, M	1
PLAUCHU, M	1
DALMAIS, J	1
GUINGAND, M	1
BOOTSMA, BK	1
SULLI, G	1
BALGOZHINA, ShZh	1
PRESNOV, MA	1
DULTSIN, MS	1
RAUSCHENBACH, MO	1
KYLE, RA	1
DAMESHEK, W	1
CLIFFORD, P	3
ORIGENES, ML	1
BEATTY, EC	1
BRUBAKER, C	1
HAMMOND, D	1
HARTMANN, JR	1
SHORE, N	1
WILLIAMS, KO	1
MOLANDER, DW	1
LADUE, JS	1
WAKISAKA, G	1
UCHINO, H	1
NAKAMURA, T	1
SHIRAKAWA, S	1
ADACHI, A	1
SAKURAI, M	1
MIYAMOTO, K	1
MURTHY, BG	1
HARMAN, JB	1
COWLING, DC	1
QUAGLINO, D	1
HAYHOE, FG	1
HUTCHISON, JL	1
ROSENOER, VM	1
WHISSON, ME	1
NELSON, BM	1
ANDREWS, GA	1
INNES, J	1
CONNORS, TA	1
LEESE, CL	1
SCOTT, RB	1
ELLISON, RR	1
LEY, AB	1
HAYASHI, S	1
UEKI, H	1
KOMIYA, J	1
CLIFT, RA	3
KHAN, AG	1
CSANYI, E	2
HORVATH, P	1
INSTITORIS, L	2
LOEB, V	1
HORVATH, PI	1
CONKLIN, JW	1
UPTON, AC	1
CHRISTENBERRY, KW	1
TALVALKAR, GV	1
MOESCHLIN, S	1
HARRAP, KR	1
SPEED, DE	1
ATHENS, JW	1
RAAB, SO	1
HAAB, OP	1
BOGGS, DR	1
ASHENBRUCKER, H	1
CARTWRIGHT, GE	1
WINTROBE, MM	1
MORROW, LB	1
ANDERSON, RE	1
BHARDWAJ, BV	1
WHITTAKER, LR	1
HUNSTEIN, W	3
HARWERTH, HG	1
RAJU, S	1
GALTON, DA	1
Kim, SW	1
Makimoto, A	1
Bouligand, J	2
Boland, I	2
Valteau-Couanet, D	8
Deroussent, A	3
Kalifa, C	3
Hartmann, O	8
Vassal, G	7
Knight, LA	1
Di Nicolantonio, F	1
Whitehouse, P	1
Mercer, S	1
Sharma, S	1
Glaysher, S	1
Johnson, P	1
Cree, IA	1
Aupérin, A	1
Michon, J	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Trial Of Double Umbilical Cord Blood Transplantation[NCT00763490]	Phase 2	20 participants (Actual)	Interventional	2008-12-31	Completed
Use of the GnRH Agonist Leuprolide Acetate (Lupron(Registered Trademark)) to Preserve Ovarian Function in Women Undergoing Chemotherapy[NCT00507780]	Phase 4	0 participants (Actual)	Interventional	2007-07-18	Withdrawn
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	percentage of participants (Number)
Double Cord Blood Tranplant	40

Event Free Survival (EFS) was determined. Patients were followed up to 5 years (median time of 2.35 years). (NCT00763490)
Timeframe: 5 Years

Cumulative Incidence of Neutrophil and Platelet Engraftment

Intervention	percentage of patients (Number)
Double Cord Blood Tranplant	35

The failure to achieve a neutrophil count > 500/uL or a platelet count >30.0 x 10e9 /L within 35 days of the stem cell infusion will be defined as primary engraftment failure. (NCT00763490)
Timeframe: Day 35

Incidence of Acute (Grade II-IV) and Chronic Graft-vs-host Disease(GVHD)

Intervention	percentage of participants (Number)
	Cumulative incidence of platlet engraftment	Cumulative incidence of neutrophil engraftment
Double Cord Blood Tranplant	73	89

"The percentage of patients with acute GVHD (Grade II-IV) was determined at 100 days. Patients were followed up to 5 years and the percentage of patients that developed chronic GVHD at the end of the study was tabulated.~Acute GVHD is staged and graded (grade 0-IV, where grade 0 is no involvement and involvement increases by grade) by the number and extent of organ involvement. Patients can have involvement of three organs: skin (rash/dermatitis), liver (hepatitis/jaundice), and gastrointestinal tract (abdominal pain/diarrhea)." (NCT00763490)
Timeframe: Up to 5 years

Article	Year
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. Nature cell biology, 2015, Volume: 17, Issue:11 Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms;	2015
The role of therapeutic drug monitoring in the management of safety of anticancer agents: a focus on 3 cytotoxics. Expert opinion on drug safety, 2019, Volume: 18, Issue:11 Topics: Antineoplastic Agents; Busulfan; Dose-Response Relationship, Drug; Drug Monitoring; Fluorouracil; Hu	2019
Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood and young adult cancer: A systematic review. Cancer treatment reviews, 2017, Volume: 53 Topics: Age Factors; Amenorrhea; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms;	2017
Reversible and irreversible protein glutathionylation: biological and clinical aspects. Expert opinion on drug metabolism & toxicology, 2011, Volume: 7, Issue:7 Topics: Alanine; Aldehydes; Alzheimer Disease; Apoptosis; Busulfan; Cataract; Cell Cycle; Cystic Fibrosis; D	2011
Do different conditioning regimens really make a difference? Hematology. American Society of Hematology. Education Program, 2012, Volume: 2012 Topics: Adult; Aged; Bone Marrow Transplantation; Busulfan; Graft vs Host Disease; Hematologic Neoplasms; Hu	2012
[Preface-importance of supportive therapies against adverse drug reactions in cancer treatment]. Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:7 Topics: Anaphylaxis; Antineoplastic Agents; Bleomycin; Busulfan; Heart; Humans; Lung; Mitomycin; Neoplasms;	2002
[Approaches to prevention of the middle to late phase adverse drug reactions in chemotherapy]. Gan to kagaku ryoho. Cancer & chemotherapy, 2002, Volume: 29, Issue:7 Topics: Antineoplastic Agents; Arrhythmias, Cardiac; Bleomycin; Busulfan; Doxorubicin; Guideline Adherence;	2002
[MEDICAL THERAPY OF MALIGNANT NEOPLASMS]. La Clinica terapeutica, 1964, Feb-29, Volume: 28 Topics: Antimetabolites; Antineoplastic Agents; Antiviral Agents; Blood Transfusion; Busulfan; Chlorambucil;	1964
PORPHYRIA CUTANEA TARDA ASSOCIATED WITH CHRONIC GRANULOCYTIC LEUKEMIA TREATED WITH BUSULFAN (MYLERAN). Blood, 1964, Volume: 23 Topics: Busulfan; Feces; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms; Pigm	1964
[Mini-transplantation for solid tumors]. Nihon rinsho. Japanese journal of clinical medicine, 2003, Volume: 61, Issue:9 Topics: Adolescent; Adult; Antilymphocyte Serum; Busulfan; Child; Child, Preschool; Clinical Trials as Topic	2003
High-dose alkylating agent therapy: a review of clinical experiences. Cancer drug delivery, 1984,Summer, Volume: 1, Issue:3 Topics: Alkylating Agents; Busulfan; Carcinoma, Bronchogenic; Carmustine; Dose-Response Relationship, Drug;	1984
Recent developments in cancer chemotherapy. Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques, 1981, Volume: 25 Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic	1981
Cancer chemotherapy in the elderly. Japanese journal of clinical oncology, 1998, Volume: 28, Issue:8 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Anthraquinones; Antineoplastic Agents; Breast Neo	1998
Immunosuppressive and cytotoxic chemotherapy: long-term complications. Annals of internal medicine, 1975, Volume: 82, Issue:1 Topics: Alkylating Agents; Antineoplastic Agents; Azathioprine; Bleomycin; Busulfan; Carcinogens; Chemical a	1975
Pulmonary toxicity of antineoplastic drugs. Cancer treatment reports, 1978, Volume: 62, Issue:12 Topics: Antineoplastic Agents; Bleomycin; Busulfan; Cyclophosphamide; Humans; Lung Diseases; Methotrexate; N	1978
Late side effects of treatment: skeletal, genetic, central nervous system, and oncogenic. Pediatric clinics of North America, 1976, Volume: 23, Issue:1 Topics: Abnormalities, Drug-Induced; Adolescent; Adult; Antineoplastic Agents; Busulfan; Carcinogens; Centra	1976
[Chemotherapy of malignant tumors]. Hippokrates, 1975, Volume: 46, Issue:3 Topics: Androgens; Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Bone Neoplasms; Breast	1975
Disorders of hemostasis and thrombosis in the aged. The Medical clinics of North America, 1976, Volume: 60, Issue:6 Topics: Adolescent; Adult; Aged; Aortic Aneurysm; Blood Coagulation Disorders; Blood Coagulation Factors; Bl	1976
Tumor inductions by cytostatics in man. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 1975, Issue:52 Topics: 2-Naphthylamine; Alkylating Agents; Antineoplastic Agents; Busulfan; Carcinogens; Cocarcinogenesis;	1975
Adoptive tumor immunotherapy in mice as an adjunct to whole-body x-irradiation and chemotherapy. A review. Israel journal of medical sciences, 1973, Volume: 9, Issue:3 Topics: Animals; Antigens, Neoplasm; Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Cyclophospham	1973
On the biological alkylating agents. Perspectives in biology and medicine, 1973,Summer, Volume: 16, Issue:4 Topics: Alkylating Agents; Busulfan; Carcinogens; Chlorambucil; Melphalan; Mustard Compounds; Mutation; Neop	1973
Cancer chemotherapy. I. New York state journal of medicine, 1972, Oct-15, Volume: 72, Issue:20 Topics: Animals; Busulfan; Chlorambucil; Cyclophosphamide; Female; Humans; Male; Mechlorethamine; Melphalan;	1972
Use of anticancer drugs during pregnancy. Clinical obstetrics and gynecology, 1968, Volume: 11, Issue:2 Topics: Alkylating Agents; Aminopterin; Animals; Antimetabolites; Antineoplastic Agents; Busulfan; Chlorambu	1968
[The cancerogenicity of antineoplastic agents]. Archiv fur Geschwulstforschung, 1969, Volume: 34, Issue:2 Topics: Aged; Alkylating Agents; Animals; Antimetabolites; Antineoplastic Agents; Busulfan; Female; Humans;	1969
[Side-effects of cytostatic therapy with special reference to potential carcinogenic effects]. Der Internist, 1971, Volume: 12 Topics: Alkylating Agents; Animals; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Bus	1971
[Alkylating cytostatic agents]. Der Internist, 1971, Volume: 12 Topics: Alkylating Agents; Alkylation; Animals; Busulfan; Cell Division; Chemical Phenomena; Chemistry; Chlo	1971

Article	Year
Conditioning therapy with N-acetyl-L-cysteine, decitabine and modified BUCY regimen for myeloid malignancies patients prior to allogeneic hematopoietic stem cell transplantation. American journal of hematology, 2023, Volume: 98, Issue:6 Topics: Acetylcysteine; Behavior Therapy; Busulfan; Decitabine; Graft vs Host Disease; Hematopoietic Stem Ce	2023
Fludarabine and intravenous busulfan conditioning with post-transplantation cyclophosphamide for allogeneic peripheral stem cell transplantation for adult patients with lymphoid malignancies: a prospective single-arm phase II study. Frontiers of medicine, 2021, Volume: 15, Issue:1 Topics: Adult; Busulfan; Cyclophosphamide; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; H	2021
Impact of Hematopoietic Stem Cell Transplantation on Dental Development. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:1 Topics: Age Factors; Allografts; Busulfan; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transpla	2019
Double umbilical cord blood transplantation after novel myeloablative conditioning using a regimen of fludarabine, busulfan, and total lymphoid irradiation. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2014, Volume: 20, Issue:12 Topics: Acute Disease; Adolescent; Adult; Aged; Busulfan; Child; Child, Preschool; Chronic Disease; Cord Blo	2014
Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration-time curve in pediatric hematopoietic stem cell transplant recipients. International journal of hematology, 2015, Volume: 102, Issue:5 Topics: Adolescent; Allografts; Area Under Curve; Busulfan; Child; Child, Preschool; Disease-Free Survival;	2015
Population pharmacokinetic study of a test dose oral busulfan in Japanese adult patients undergoing hematopoietic stem cell transplantation. Cancer chemotherapy and pharmacology, 2010, Volume: 65, Issue:6 Topics: Administration, Oral; Adolescent; Adult; Aged; Algorithms; Antineoplastic Agents, Alkylating; Area U	2010
Long-term follow-up of children conditioned with Treosulfan: German and Austrian experience. Bone marrow transplantation, 2013, Volume: 48, Issue:4 Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Austria; Bone Marrow Transplantation; Busulfan	2013
A new minimally ablative stem cell transplantation procedure in high-risk patients not eligible for nonmyeloablative allogeneic bone marrow transplantation. Bone marrow transplantation, 2003, Volume: 32, Issue:6 Topics: Adult; Busulfan; Cyclosporine; Female; Graft Survival; Graft vs Host Disease; Hematopoietic Stem Cel	2003
In children and adolescents, the pharmacodynamics of high-dose busulfan is dependent on the second alkylating agent used in the combined regimen (melphalan or thiotepa). Bone marrow transplantation, 2003, Volume: 32, Issue:10 Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols	2003
Cost effectiveness of day 5 G-CSF (Lenograstim) administration after PBSC transplantation: results of a SFGM-TC randomised trial. Bone marrow transplantation, 2005, Volume: 36, Issue:6 Topics: Adolescent; Adult; Aged; Blood Transfusion; Busulfan; Child; Child, Preschool; Cost-Benefit Analysis	2005
Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer chemotherapy and pharmacology, 2006, Volume: 57, Issue:2 Topics: Adult; Antineoplastic Agents, Alkylating; Area Under Curve; Busulfan; Cyclophosphamide; Female; Hema	2006
Pharmacokinetics of a test dose of intravenous busulfan guide dose modifications to achieve an optimal area under the curve of a single daily dose of intravenous busulfan in children undergoing a reduced-intensity conditioning regimen with hematopoietic s Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2006, Volume: 12, Issue:4 Topics: Adolescent; Area Under Curve; Busulfan; Child; Child, Preschool; Disease-Free Survival; Female; Graf	2006
Population pharmacokinetic-based dosing of intravenous busulfan in pediatric patients. Journal of clinical pharmacology, 2007, Volume: 47, Issue:1 Topics: Age Factors; Alkylating Agents; Body Surface Area; Body Weight; Busulfan; Child; Child, Preschool; C	2007
Elevated plasma ferritin and busulfan pharmacodynamics during high-dose chemotherapy regimens in children with malignant solid tumors. Clinical pharmacology and therapeutics, 2007, Volume: 82, Issue:4 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Preschool; Cyclo	2007
Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer chemotherapy and pharmacology, 2008, Volume: 61, Issue:1 Topics: Adolescent; Age Factors; Antineoplastic Agents, Alkylating; Area Under Curve; Body Weight; Busulfan;	2008
Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stem cell support in patients with refractory malignancies. Bone marrow transplantation, 1994, Volume: 14, Issue:5 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan; Combi	1994
Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for marrow transplantation: risk factors for early regimen-related toxicity. Annals of hematology, 1994, Volume: 68, Issue:4 Topics: Adult; Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Female; Hematologic Diseases; Humans	1994
Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. Bone marrow transplantation, 1996, Volume: 17, Issue:6 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Busulfan;	1996
Clinical pharmacokinetics of intravenous treosulfan in patients with advanced solid tumors. Cancer chemotherapy and pharmacology, 1998, Volume: 42, Issue:2 Topics: Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Female; Humans; Infusions, Intravenous; Ma	1998
High-dose busulfan/melphalan as conditioning for autologous PBPC transplantation in pediatric patients with solid tumors. Bone marrow transplantation, 1999, Volume: 24, Issue:11 Topics: Adolescent; Adult; Antigens, CD34; Antineoplastic Agents, Alkylating; Blood Cell Count; Bone Disease	1999
Clinical phase I dose escalation and pharmacokinetic study of high-dose chemotherapy with treosulfan and autologous peripheral blood stem cell transplantation in patients with advanced malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 2000, Volume: 6, Issue:11 Topics: Adult; Antineoplastic Agents, Alkylating; Busulfan; Female; Hematopoietic Stem Cell Transplantation;	2000
Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clinical cancer research : an official journal of the American Association for Cancer Research, 2001, Volume: 7, Issue:8 Topics: Acute Disease; Adolescent; Adult; Aged; Antilymphocyte Serum; Antineoplastic Combined Chemotherapy P	2001
Oral anticoagulant therapy of human cancer. Journal of medicine, 1974, Volume: 5, Issue:1 Topics: Administration, Oral; Anticoagulants; Antineoplastic Agents; Breast Neoplasms; Busulfan; Chlorambuci	1974
Clinical trial with dihydroxybusulfan (NSC-39069). Cancer chemotherapy reports, 1968, Volume: 52, Issue:5 Topics: Busulfan; Clinical Trials as Topic; Humans; Neoplasms	1968

Article	Year
Cumulative incidence of subsequent malignancy after allo-HCT conditioned with or without low-dose total body irradiation. Blood advances, 2022, 02-08, Volume: 6, Issue:3 Topics: Busulfan; Hematopoietic Stem Cell Transplantation; Humans; Incidence; Neoplasms; Transplantation Con	2022
Incidence of subsequent malignancies after total body irradiation-based allogeneic HSCT in children with ALL - long-term follow-up from the prospective ALL-SCT 2003 trial. Leukemia, 2022, Volume: 36, Issue:11 Topics: Busulfan; Child; Cyclophosphamide; Etoposide; Follow-Up Studies; Graft vs Host Disease; Hematopoieti	2022
A case-control study of Clostridioides difficile symptomatic infections in a pediatric cancer hospital. Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo, 2023, Volume: 41 Topics: Anti-Bacterial Agents; Asparaginase; Busulfan; Cancer Care Facilities; Carboplatin; Case-Control Stu	2023
Efficacy of venetoclax combined with decitabine conditioning regimen for allogeneic hematopoietic stem cell transplantation in high-risk and elderly patients with myeloid neoplasms. Annals of hematology, 2023, Volume: 102, Issue:12 Topics: Aged; Busulfan; Decitabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans;	2023
Assessment of Chemotherapy-Induced Organ Damage with Ga-68 Labeled Duramycin. Molecular imaging and biology, 2020, Volume: 22, Issue:3 Topics: Acetates; Animals; Antineoplastic Combined Chemotherapy Protocols; Bacteriocins; Busulfan; Cisplatin	2020
Factors predicting endocrine late effects in childhood cancer survivors from a Japanese hospital. Endocrine journal, 2020, Feb-28, Volume: 67, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents; Brain Neoplasms; Busulfan; Cancer Survivors; Child; Chroni	2020
Thiotepa-busulfan-fludarabine (TBF) conditioning regimen in patients undergoing allogeneic hematopoietic cell transplantation for myelofibrosis: an outcome analysis from the Chronic Malignancies Working Party of the EBMT. Bone marrow transplantation, 2021, Volume: 56, Issue:7 Topics: Busulfan; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Neopl	2021
Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence. European journal of cancer (Oxford, England : 1990), 2018, Volume: 91 Topics: Adolescent; Age Factors; Antineoplastic Agents; Area Under Curve; Busulfan; Carboplatin; Child; Chil	2018
Synergistic Cytotoxic Effect of Busulfan and the PARP Inhibitor Veliparib in Myeloproliferative Neoplasms. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2019, Volume: 25, Issue:5 Topics: Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Benzimid	2019
Pharmacokinetics: Unique Challenges in Blood Monitoring for Oncology Nurses. Clinical journal of oncology nursing, 2019, 04-01, Volume: 23, Issue:2 Topics: Aged; Antineoplastic Agents, Alkylating; Busulfan; Drug Monitoring; Humans; Male; Neoplasms; Vascula	2019
A proposed dynamic dosing scheme to secure the target plasma drug concentrations based on the precision of the AUC estimate. Studies in health technology and informatics, 2013, Volume: 192 Topics: Antineoplastic Agents, Alkylating; Busulfan; Computer Simulation; Drug Therapy, Computer-Assisted; H	2013
Adult testicular volume predicts spermatogenetic recovery after allogeneic HSCT in childhood and adolescence. Pediatric blood & cancer, 2014, Volume: 61, Issue:6 Topics: Adolescent; Allografts; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Pres	2014
Age-dependent pharmacokinetic profile of single daily dose i.v. busulfan in children undergoing reduced-intensity conditioning stem cell transplant. Bone marrow transplantation, 2009, Volume: 44, Issue:3 Topics: Adolescent; Age Factors; Busulfan; Child; Child, Preschool; Disease-Free Survival; Hematopoietic Ste	2009
MicroRNA regulation of ionizing radiation-induced premature senescence. International journal of radiation oncology, biology, physics, 2011, Nov-01, Volume: 81, Issue:3 Topics: Busulfan; Cell Line; Cellular Senescence; DNA Damage; Down-Regulation; Fibroblasts; Gene Silencing;	2011
Permanent alopecia after systemic chemotherapy: a clinicopathological study of 10 cases. The American Journal of dermatopathology, 2011, Volume: 33, Issue:4 Topics: Alopecia; Antineoplastic Agents; Busulfan; Cisplatin; Dermis; Diagnosis, Differential; Docetaxel; Et	2011
Physiologically based pharmacokinetic modelling of high- and low-dose etoposide: from adults to children. Cancer chemotherapy and pharmacology, 2012, Volume: 69, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols	2012
A comparison of immune reconstitution and graft-versus-host disease following myeloablative conditioning versus reduced toxicity conditioning and umbilical cord blood transplantation in paediatric recipients. British journal of haematology, 2011, Volume: 155, Issue:2 Topics: Alemtuzumab; Antibiotic Prophylaxis; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antily	2011
Population pharmacokinetics of busulfan in children: increased evidence for body surface area and allometric body weight dosing of busulfan in children. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011, Nov-01, Volume: 17, Issue:21 Topics: Adolescent; Antineoplastic Agents, Alkylating; Body Surface Area; Body Weight; Bone Marrow Transplan	2011
Once-daily intravenous busulfan for 47 pediatric patients undergoing autologous hematopoietic stem cell transplantation: a single center study. Journal of pediatric hematology/oncology, 2012, Volume: 34, Issue:3 Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Combined Modality Therapy; Drug Administration	2012
Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood, 2003, Jul-15, Volume: 102, Issue:2 Topics: Acute Disease; Adolescent; Adult; Antilymphocyte Serum; Busulfan; Chronic Disease; Disease Progressi	2003
Decreased transfusion requirements in patients given stem cell allografts using a non-myeloablative conditioning regimen: a single institution experience. Hematology (Amsterdam, Netherlands), 2003, Volume: 8, Issue:3 Topics: Adolescent; Adult; Busulfan; Child; Child, Preschool; Cyclophosphamide; Cyclosporine; Erythrocyte Tr	2003
Population pharmacokinetics of oral busulfan in children. Cancer chemotherapy and pharmacology, 2003, Volume: 52, Issue:3 Topics: Administration, Oral; Antineoplastic Agents, Alkylating; Area Under Curve; Body Surface Area; Busulf	2003
Clinical features and treatment of hematopoietic stem cell transplantation-associated gastric antral vascular ectasia. Bone marrow transplantation, 2003, Volume: 32, Issue:4 Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Biopsy; Busulfan; Endothelium, Vascular; Femal	2003
Reduced-intensity preparative regimen and allogeneic stem cell transplantation for advanced solid tumors. Blood, 2004, Jan-15, Volume: 103, Issue:2 Topics: Acute Disease; Adult; Antilymphocyte Serum; Bone Marrow Transplantation; Busulfan; Chronic Disease;	2004
[Effect of GT-41 (Myleran) on tumor cells of the MTK-sarcoma III]. Gan, 1955, Volume: 46, Issue:2-3 Topics: Animals; Busulfan; Glycols; Neoplasms; Sarcoma; Sarcoma, Experimental	1955
Myleran therapy in malignant neoplastic disease; use of 1,4-dimethanesulfonyloxbutane with emphasis on chronic granulocytic leukemia. Journal of the American Medical Association, 1956, Jun-30, Volume: 161, Issue:9 Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasms	1956
Distribution and metabolic fate of S35-labeled myleran (busulfan) in normal and tumor-bearing rats. The Journal of pharmacology and experimental therapeutics, 1957, Volume: 120, Issue:2 Topics: Animals; Busulfan; Neoplasms; Neoplasms, Experimental; Rats	1957
Tumour-inhibiting action of 1 : 6-dimethanesulphonyl-D-mannitol. Nature, 1958, Oct-25, Volume: 182, Issue:4643 Topics: Antineoplastic Agents; Busulfan; Humans; Mannitol; Neoplasms	1958
Clinical trials of nonane in malignant disease. Annals of the New York Academy of Sciences, 1958, Apr-24, Volume: 68, Issue:3 Topics: Alkanes; Busulfan; Humans; Neoplasms	1958
The influence of 1, 4-dimethylsulfonoxy-1, 4-dimethylbutane (CB 2348, dimethyl myleran) in neoplastic disease. Annals of the New York Academy of Sciences, 1958, Apr-24, Volume: 68, Issue:3 Topics: Busulfan; Leadership; Neoplasms	1958
Evaluation of chemotherapy in ovarian and cervical cancer by tissue culture methods. American journal of obstetrics and gynecology, 1959, Volume: 77, Issue:4 Topics: Antineoplastic Agents; Busulfan; Female; Humans; Mechlorethamine; Neoplasms; Nitrogen Mustard Compou	1959
[Effect of the association of 6-mercaptopurine-chlorambucil and 6-mercaptopurine-myleran on the growth of Galliera sarcoma in the rat]. Bollettino della Societa italiana di biologia sperimentale, 1960, Jun-30, Volume: 36 Topics: Animals; Antineoplastic Agents; Busulfan; Chlorambucil; Mercaptopurine; Neoplasms; Rats; Sarcoma	1960
Chemotherapy of malignant disease. II. Diseases of lymphoid tissue and bone marrow. The Medical journal of Australia, 1962, Dec-01, Volume: 49(2) Topics: Adrenal Cortex Hormones; Aged; Bone Marrow; Busulfan; Chlorambucil; Cyclophosphamide; Hodgkin Diseas	1962
The chemotherapy of intrathoracic tumors. Diseases of the chest, 1962, Volume: 42 Topics: Busulfan; Chlorambucil; Cyclophosphamide; Dactinomycin; Humans; Mechlorethamine; Methotrexate; Neopl	1962
Effect of anti-tumour agents on non-dividing cells. Nature, 1962, Nov-17, Volume: 196 Topics: Antineoplastic Agents; Busulfan; Cobalt Isotopes; Mechlorethamine; Megakaryocytes; Neoplasms; Trieth	1962
Addendum to report on mannitol myleran (NSC-37538). Cancer chemotherapy reports, 1962, Volume: 23 Topics: Busulfan; Humans; Mannitol; Neoplasms	1962
Mannitol myleran. Cancer chemotherapy reports, 1962, Volume: 23 Topics: Busulfan; Mannitol; Neoplasms; Neoplasms, Experimental	1962
Chronic granulocytic leukemia and cancer. Report of a case. Blood, 1963, Volume: 22 Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mercaptopurine; Neoplasms; Rad	1963
DIFFUSE INTERSTITIAL PULMONARY FIBROSIS AFTER BUSULPHAN THERAPY. Lancet (London, England), 1963, Aug-31, Volume: 2, Issue:7305 Topics: Busulfan; Diagnosis, Differential; Ergocalciferols; Humans; Leukemia; Leukemia, Myeloid; Neoplasms;	1963
EXPERIMENTAL APPROACHES TO THE CHEMOTHERAPY OF LEUKAEMIA. Proceedings of the Royal Society of Medicine, 1963, Volume: 56 Topics: Busulfan; Chlorambucil; Leukemia; Leukemia, Experimental; Neoplasms; Rats; Research	1963
LEUKEMIA. AN ANALYSIS OF 209 CASES FROM THE ELLIS FISCHEL STATE CANCER HOSPITAL. Missouri medicine, 1963, Volume: 60 Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antineoplastic Agents; Busulfan; Cancer Care Facilit	1963
[STUDIES ON ANTITUMOR DRUGS. III. THE USE OF IN VITRO CULTURE OF YOSHIDA ASCITES SARCOMA CELLS IN SCREENING ANTITUMOR SUBSTANCES]. Yao xue xue bao = Acta pharmaceutica Sinica, 1963, Volume: 10 Topics: Animals; Antineoplastic Agents; Ascites; Busulfan; Chemical Phenomena; Chemistry; In Vitro Technique	1963
EFFECT OF ADMINISTRATION OF ALKYLATING AGENTS OR 6-MERCAPTOPURINE ON SERUM LEVEL OF DEOXYRIBONUCLEASE I IN LEUKEMIA PATIENTS. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.), 1963, Volume: 114 Topics: Alkylating Agents; Blood Chemical Analysis; Busulfan; Deoxyribonuclease I; DNA; Humans; Leukemia; Le	1963
[MALIGNANT HISTOPLASMOCYTOSIS (A STATISTICO-CLINICAL STUDY)]. Il Policlinico. Sezione medica, 1963, Volume: 70 Topics: Adrenal Cortex Hormones; Albuminuria; Alkaline Phosphatase; Androgens; Asthenia; Blood Protein Elect	1963
THE TREATMENT OF LEUKEMIA. The New England journal of medicine, 1964, Mar-12, Volume: 270 Topics: Antineoplastic Agents; Busulfan; Chlorambucil; Cyclophosphamide; Leukemia; Mercaptopurine; Methotrex	1964
[REMOTE RESULTS OF MYELOSAN THERAPY OF CHRONIC MYELOID LEUKEMIA]. Problemy gematologii i perelivaniia krovi, 1963, Volume: 8 Topics: Busulfan; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid; Neoplasms	1963
[CHRONIC LEUKEMIA. RECENT DATA ON ITS DIAGNOSIS AND TREATMENT]. Concours medical, 1963, Nov-16, Volume: 85 Topics: Busulfan; Child; Chronic Disease; Leukemia; Leukemia, Myeloid; Neoplasms	1963
[PRESENT STATUS OF LEUKEMIA CHEMOTHERAPY]. La Revue du praticien, 1963, Dec-09, Volume: 13 Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Busulfan; Folic Acid Antagonists; Humans; Leukemia;	1963
DRUGS OF CURRENT USE FOR THE TREATMENT OF CANCER AND ALLIED DISEASES. Diseases of the chest, 1963, Volume: 51 Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Antineoplastic Agents; Aziridines; Busulfan; Colchic	1963
[REPEATED THERAPY OF CHRONIC MYELOSES BY COMBINED APPLICATION OF MYLERAN AND IRRADIATION OF THE SPLEEN]. Neoplasma, 1963, Volume: 10 Topics: Busulfan; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myeloproliferative Disorders; Ne	1963
[HOW TO TREAT LEUKEMIA IN 1963]. Revue medicale de Liege, 1963, Dec-15, Volume: 18 Topics: Busulfan; Child; Chlorambucil; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Mercaptopuri	1963
[THERAPEUTIC SYNERGISM AS A PROBABLE EXPLANATION FOR THE COMBINED EFFECT OF X-RAY IRRADIATION AND MYLERAN IN CHRONIC MYELOSES]. Neoplasma, 1964, Volume: 11 Topics: Busulfan; Hemoglobinometry; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukocyte Coun	1964
[EARLY DIAGNOSIS AND MEDICAL THERAPY OF MALIGNANT TUMORS]. Il Cancro, 1963, Volume: 16 Topics: Antineoplastic Agents; Busulfan; Colchicine; Early Diagnosis; Hodgkin Disease; Mechlorethamine; Merc	1963
CHRONIC MYELOID LEUKEMIA WITH PRIAPISM IN EIGHT-YEAR-OLD CHILD. New York state journal of medicine, 1964, Feb-15, Volume: 64 Topics: Blood Chemical Analysis; Blood Platelets; Busulfan; Child; Chromosome Aberrations; Erythrocyte Count	1964
[MEDULLARY APLASIA DURING THE USE OF 4 ANTIMITOTICS: CARYOLYSIN, MYLERAN, THIOTEPA, ENDOXAN (APROPOS OF 32 CASES)]. Journal de medecine de Lyon, 1963, Dec-05, Volume: 44 Topics: Anemia; Anemia, Aplastic; Antimitotic Agents; Busulfan; Cyclophosphamide; Neoplasms; Nitrogen Mustar	1963
[EXPERIENCE IN THE TREATMENT OF MALIGNANT DISEASES OF THE RETICULOENDOTHELIAL SYSTEM AND LEUKEMIAS. II]. Nederlands militair geneeskundig tijdschrift, 1964, Volume: 17 Topics: Betamethasone; Busulfan; Chlorambucil; Copper; Cyclophosphamide; Dexamethasone; Genetic Diseases, X-	1964
[MYELOBLASTIC ATTACKS IN CHRONIC MYELOLEUKOSIS AND THEIR TREATMENT]. Terapevticheskii arkhiv, 1963, Volume: 35 Topics: Busulfan; Leukemia; Leukemia, Myeloid; Neoplasms; Toxicology	1963
HISTOLOGICAL AND HISTOCHEMICAL DATA ON THE PROCESS OF REGRESSION OF EXPERIMENTAL TUMOURS INDUCED BY ALKYLATING AGENTS. Acta - Unio Internationalis Contra Cancrum, 1964, Volume: 20 Topics: Alkaline Phosphatase; Alkylating Agents; Animals; Antineoplastic Agents; Aziridines; Busulfan; Carci	1964
ON THE MECHANISM OF RESISTANCE TOWARDS ANTILEUKAEMIC AGENTS. Acta - Unio Internationalis Contra Cancrum, 1964, Volume: 20 Topics: Adrenocorticotropic Hormone; Anti-Bacterial Agents; Antibiotics, Antitubercular; Antineoplastic Agen	1964
THE MANAGEMENT OF MALIGNANT DISEASE OF THE HEAD AND NECK AREA IN EAST AFRICA. Acta - Unio Internationalis Contra Cancrum, 1964, Volume: 20 Topics: Africa; Africa, Eastern; Black People; Burkitt Lymphoma; Busulfan; Carcinoma, Squamous Cell; Child;	1964
TRIAL OF HYDROXYUREA (NSC-32065) IN CANCER IN CHILDREN. Cancer chemotherapy reports, 1964, Volume: 37 Topics: Antineoplastic Agents; Busulfan; Child; Cyclophosphamide; Dactinomycin; Humans; Hydroxyurea; Leukemi	1964
CHRONIC LEUKEMIA. Geriatrics, 1964, Volume: 19 Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Alkylating Agents; Anemia; Anemia, Hemolytic,	1964
PRESENT STATUS OF LEUKEMIA IN JAPAN WITH SPECIAL REFERENCE TO EPIDEMIOLOGY AND STUDIES ON THE EFFECT OF CHEMOTHERAPY. Acta haematologica, 1964, Volume: 31 Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Asian People; Busulfan; DNA; DNA, Neoplasm; Epidemio	1964
SKIN LESIONS IN CHRONIC MYELOID LEUKAEMIA. Journal of the Indian Medical Association, 1964, Jun-01, Volume: 42 Topics: Blood Transfusion; Busulfan; Dermatology; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL	1964
THE TREATMENT OF INCURABLE MALIGNANT DISEASE. Nursing times, 1964, Jun-26, Volume: 60 Topics: Adrenalectomy; Androgens; Breast Neoplasms; Busulfan; Chlorambucil; Estrogens; Heroin; Hormones; Hum	1964
PLASMA FACTORS IN LEUKAEMIA. IMMUNOLOGICAL AND "IN VITRO" CULTURAL STUDIES. Acta haematologica, 1964, Volume: 31 Topics: Blood Group Antigens; Busulfan; Chlorambucil; Complement Fixation Tests; Coombs Test; Humans; In Vit	1964
THE MANAGEMENT OF LEUKEMIA AND LYMPHOMA. Applied therapeutics, 1964, Volume: 6 Topics: Adrenal Cortex Hormones; Busulfan; Chlorambucil; Cortisone; Cyclophosphamide; Hodgkin Disease; Human	1964
A TRANSPLANTABLE PLASMA CELL TUMOUR IN THE STUDY OF CARCINOSTATIC AGENTS. Biochemical pharmacology, 1964, Volume: 13 Topics: Animals; Blood Protein Electrophoresis; Busulfan; Cyclophosphamide; Freund's Adjuvant; gamma-Globuli	1964
BREAST CANCER AND CYTOLOGIC DYSPLASIA IN MANY ORGANS AFTER BUSULFAN (MYLERAN). American journal of clinical pathology, 1964, Volume: 42 Topics: Breast Neoplasms; Busulfan; Drug Therapy; Humans; Hyperplasia; Leukemia; Leukemia, Myeloid; Neoplasm	1964
ANTI-LEUKAEMIC DRUGS. The Practitioner, 1964, Volume: 193 Topics: Busulfan; Chlorambucil; Cyclophosphamide; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; M	1964
THE EFFECT OF GLUCOSE PRETREATMENT ON THE ANTI-TUMOUR ACTION OF MANNITOL MYLERAN. Biochemical pharmacology, 1964, Volume: 13 Topics: Anuria; Arginine Vasopressin; Blood; Busulfan; Chromatography; Colorimetry; Fluids and Secretions; G	1964
A CLINICAL STUDY OF TWENTY CASES OF ERYTHROLEUKEMIA (DI GUGLIELMO'S SYNDROME). The American journal of medicine, 1964, Volume: 37 Topics: Adrenal Cortex Hormones; Azaserine; Busulfan; Diagnosis, Differential; Drug Therapy; Humans; Leukemi	1964
STUDIES ON ANTITUMOR SUBSTANCES. IV. ANTITUMOR EFFECT OF DIMETHANESULFONYL THIOALKANES. Gan, 1964, Volume: 55 Topics: Acid Phosphatase; Alkaline Phosphatase; Animals; Antineoplastic Agents; Busulfan; Carbohydrate Metab	1964
DIMETHYL MYLERAN THERAPY COMBINED WITH ABDOMINAL AORTIC OCCLUSION. British journal of cancer, 1964, Volume: 13 Topics: Adolescent; Alopecia; Aorta; Aorta, Abdominal; Busulfan; Chemotherapy, Cancer, Regional Perfusion; D	1964
[ON THE EFFECT OF GLUCOSE ON THE TOXIC AND THERAPEUTIC EFFECTS OF 1,6-DIBROMO-1,6-D-DIDESOXYMANNITOL IN ANIMAL EXPERIMENTS]. Neoplasma, 1964, Volume: 11 Topics: Aminopterin; Animal Experimentation; Animals; Antineoplastic Agents; Busulfan; Carcinoma, Ehrlich Tu	1964
DIHYDROXYBUSULFAN (NSC-39069) IN CHRONIC MYELOCYTIC LEUKEMIA AND MISCELLANEOUS MALIGNANT NEOPLASMS. Cancer chemotherapy reports, 1964, Volume: 42 Topics: Busulfan; Drug Therapy; Geriatrics; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leuk	1964
[TUMOR INHIBITORY, HEMATOLOGICAL AND TOXICOLOGICAL EFFECTS OF 1,6-DIBROMO-1,6-DIDESOXY-D-MANNITOL]. Arzneimittel-Forschung, 1964, Volume: 14 Topics: Antineoplastic Agents; Busulfan; Hematopoiesis; Kidney; Liver; Mannitol; Mice; Neoplasm Transplantat	1964
FURTHER OBSERVATIONS ON LATE SOMATIC EFFECTS OF RADIOMIMETIC CHEMICALS AND X-RAYS IN MICE. Cancer research, 1965, Volume: 25 Topics: Aging; Busulfan; Cataract; Female; Humans; Leukemia; Leukemia, Myeloid; Longevity; Lung Neoplasms; L	1965
CHRONIC MYELOID LEUKAEMIA IN CHILDREN. The Journal of the Association of Physicians of India, 1965, Volume: 13 Topics: Adolescent; Busulfan; Child; Humans; India; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positi	1965
[MODERN TREATMENT OF LEUKEMIA]. Schweizerische medizinische Wochenschrift, 1965, Feb-13, Volume: 95 Topics: Agranulocytosis; Busulfan; Chlorambucil; Cyclophosphamide; Drug Therapy; Genetic Diseases, X-Linked;	1965
SOME BIOCHEMICAL ASPECTS OF LEUKAEMIAS: THE APPEARANCE OF A SOLUBLE DISULPHIDE IN THE BLOOD IN CHRONIC GRANULOCYTIC LEUKAEMIA. British journal of cancer, 1964, Volume: 18 Topics: Biochemical Phenomena; Biochemistry; Blood Chemical Analysis; Busulfan; Disulfides; Erythrocytes; Gl	1964
LEUKOKINETIC STUDIES. X. BLOOD GRANULOCYTE KINETICS IN CHRONIC MYELOCYTIC LEUKEMIA. The Journal of clinical investigation, 1965, Volume: 44 Topics: Bone Marrow Cells; Bone Marrow Transplantation; Busulfan; Cell Division; Colchicine; Granulocytes; H	1965
ACTIVE TUBERCULOSIS IN LEUKEMIA. MALIGNANT LYMPHOMA AND MYELOFIBROSIS. Archives of pathology, 1965, Volume: 79 Topics: Alkylating Agents; Aminopterin; Busulfan; Hodgkin Disease; Humans; Leukemia; Leukemia, Lymphoid; Leu	1965
INTENSIVE NITROGEN MUSTARD THERAPY WITH ABDOMINAL AORTIC OCCLUSION IN NASOPHARYNGEAL CARCINOMA. British journal of cancer, 1965, Volume: 19 Topics: Adenocarcinoma; Antineoplastic Agents; Aorta; Aorta, Abdominal; Busulfan; Carcinoma; Carcinoma, Squa	1965
[BIOPTIC STUDIES ON THE PROBLEM OF THERAPY-INDUCED BONE MARROW FIBROSES IN CHRONIC MYELOID LEUKEMIA]. Medizinische Klinik, 1965, Jun-18, Volume: 60 Topics: Busulfan; Drug Therapy; Humans; Leukemia; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia	1965
CLINICAL TRIALS IN PROGRESS: LEUKAEMIA AND MULTIPLE MYELOMA. Proceedings of the Royal Society of Medicine, 1965, Volume: 58 Topics: Adolescent; Antineoplastic Agents; Busulfan; Child; Cyclophosphamide; Drug Therapy; Humans; Infant;	1965
DEATH after new drug. British medical journal, 1950, Sep-09, Volume: 2, Issue:4679 Topics: Busulfan; Humans; Neoplasms	1950
The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours. BMC cancer, 2004, Nov-23, Volume: 4 Topics: Adenocarcinoma; Adenosine Triphosphate; Antineoplastic Combined Chemotherapy Protocols; Breast Neopl	2004
Cataracts among cancer survivors. American journal of clinical oncology, 2005, Volume: 28, Issue:6 Topics: Adrenal Cortex Hormones; Adult; Aging; Bone Marrow Transplantation; Breast Neoplasms; Busulfan; Cata	2005
[Metronomic chemotherapy. Should we change our thinking in the treatment of advanced tumors?]. Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG, 2005, Volume: 3, Issue:1 Topics: Administration, Oral; Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Human	2005
Modelling competing risks in cancer studies. Statistics in medicine, 2006, Mar-30, Volume: 25, Issue:6 Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplant	2006
Successful stem cell transplantation in an infant with severe congenital neutropenia complicated by pretransplant inflammatory pseudotumor of the liver. Bone marrow transplantation, 2006, Volume: 38, Issue:9 Topics: Antilymphocyte Serum; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protoc	2006
Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic d Blood, 2007, Aug-15, Volume: 110, Issue:4 Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Child, Pre	2007
Sister chromatid exchanges in human lymphocytes exposed to single cytotoxic drugs in vivo or in vitro. European journal of cancer & clinical oncology, 1982, Volume: 18, Issue:10 Topics: Adult; Aged; Antineoplastic Agents; Busulfan; Cells, Cultured; Chlorambucil; Crossing Over, Genetic;	1982
Increased cancer risk in canine radiation chimeras. Blood, 1980, Volume: 55, Issue:2 Topics: Aging; Animals; Bone Marrow Transplantation; Busulfan; Central Nervous System Diseases; Cyclophospha	1980
Busulfan concentration in relation to permanent alopecia in recipients of bone marrow transplants. Bone marrow transplantation, 1995, Volume: 15, Issue:6 Topics: Adolescent; Adult; Alopecia; Anemia, Aplastic; Bone Marrow Transplantation; Busulfan; Child; Child,	1995
Prolonged impairment of hematopoiesis after high-dose therapy followed by autologous bone marrow transplantation. Blood, 1995, Jun-01, Volume: 85, Issue:11 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Bone Marrow Transpla	1995
The effects of bone marrow transplantation on pulmonary function in children. Pediatric pulmonology, 1994, Volume: 18, Issue:6 Topics: Adolescent; Age Factors; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Cytomegalov	1994
Busulfan-containing pre-transplant regimens for the treatment of solid tumors. Bone marrow transplantation, 1994, Volume: 14, Issue:3 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Brea	1994
Pharmacokinetics of undiluted or diluted high-dose etoposide with or without busulfan administered to patients with hematologic malignancies. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1994, Volume: 12, Issue:7 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child; Chromatography,	1994
Busulphan and melphalan prior to autologous bone marrow transplantation. Bone marrow transplantation, 1993, Volume: 12, Issue:4 Topics: Actuarial Analysis; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone	1993
Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer chemotherapy and pharmacology, 1996, Volume: 37, Issue:3 Topics: Adolescent; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Bone	1996
Malignancies after marrow transplantation for aplastic anemia and fanconi anemia: a joint Seattle and Paris analysis of results in 700 patients. Blood, 1996, Jan-01, Volume: 87, Issue:1 Topics: Adolescent; Adult; Aged; Anemia, Aplastic; Bone Marrow Transplantation; Busulfan; Child; Child, Pres	1996
Hepatic dysfunction following busulfan and cyclophosphamide myeloablation: a retrospective, multicenter analysis. Bone marrow transplantation, 1996, Volume: 18, Issue:1 Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bone Marrow Transplantation; Busulfan; Child; Child,	1996
Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone marrow transplantation, 1997, Volume: 20, Issue:10 Topics: Adolescent; Adult; Anticoagulants; Antithrombin III; Bone Marrow Transplantation; Busulfan; Child; C	1997
Double-conditioning regimens consisting of thiotepa, melphalan and busulfan with stem cell rescue for the treatment of pediatric solid tumors. Bone marrow transplantation, 1998, Volume: 22, Issue:1 Topics: Adolescent; Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Busulfan; Child;	1998
Ovarian function after autologous bone marrow transplantation in childhood: high-dose busulfan is a major cause of ovarian failure. Bone marrow transplantation, 1998, Volume: 22, Issue:10 Topics: Adolescent; Adult; Antineoplastic Agents, Alkylating; Bone Marrow Transplantation; Busulfan; Child;	1998
[Increased apoptosis of peripheral blood leukocytes correlates with leukopenia after high-dose chemotherapy]. Voprosy onkologii, 1999, Volume: 45, Issue:4 Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Busulf	1999
Dose-reduced conditioning for allogeneic blood stem cell transplantation: durable engraftment without antithymocyte globulin. Bone marrow transplantation, 2000, Volume: 26, Issue:2 Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Busulfan; Disease-Free Survival; Female; G	2000
Pilot trial of cytoprotection with amifostine given with high-dose chemotherapy and autologous peripheral blood stem cell transplantation. American journal of clinical oncology, 2000, Volume: 23, Issue:4 Topics: Adult; Aged; Amifostine; Antiemetics; Antineoplastic Agents, Alkylating; Antineoplastic Combined Che	2000
Idiopathic pneumonia syndrome following myeloablative chemotherapy and autologous transplantation. The Annals of pharmacotherapy, 2001, Volume: 35, Issue:2 Topics: Adolescent; Adult; Aged; Antineoplastic Agents, Alkylating; Busulfan; Child; Child, Preschool; Femal	2001
[Pulmonary fibrosis following treatment with cytostatics]. Wiener medizinische Wochenschrift (1946), 1976, Oct-01, Volume: 126, Issue:40 Topics: Antineoplastic Agents; Bleomycin; Busulfan; Humans; Male; Melphalan; Methotrexate; Middle Aged; Neop	1976
[Fetal risk of cancer chemotherapy (author's transl)]. Bulletin du cancer, 1979, Volume: 66, Issue:2 Topics: Abnormalities, Drug-Induced; Abortion, Spontaneous; Adult; Alkaloids; Animals; Antibiotics, Antineop	1979
Sister-chromatid exchanges and chromosal breakage in patients treated with cytostatics. Mutation research, 1979, Volume: 67, Issue:3 Topics: Bromodeoxyuridine; Busulfan; Chromatids; Chromosome Aberrations; Cyclophosphamide; Doxorubicin; Fluo	1979
[Tumor-induction through cytostatic agents in man]. Deutsche medizinische Wochenschrift (1946), 1975, Jan-24, Volume: 100, Issue:4 Topics: Antineoplastic Agents; Breast Neoplasms; Busulfan; Carcinogens; Cyclophosphamide; Humans; Leukemia,	1975
Treatment of recurrent and refractory pediatric solid tumors with high-dose busulfan and cyclophosphamide followed by autologous bone marrow rescue. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1992, Volume: 10, Issue:12 Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Purging; Bone Marrow	1992
Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone marrow transplantation, 1992, Volume: 10, Issue:2 Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Female; Hepatic Veno-Occ	1992
Dose-dependent neurotoxicity of high-dose busulfan in children: a clinical and pharmacological study. Cancer research, 1990, Oct-01, Volume: 50, Issue:19 Topics: Adolescent; Busulfan; Child; Child, Preschool; Drug Evaluation; Humans; Infant; Neoplasms; Seizures	1990
Pharmacokinetics of high-dose busulfan in children. Cancer chemotherapy and pharmacology, 1989, Volume: 24, Issue:6 Topics: Adolescent; Bone Marrow Transplantation; Busulfan; Child; Child, Preschool; Combined Modality Therap	1989
Expression of messenger RNA for GM-CSF by blood mononuclear cells after allogeneic bone marrow transplantation. Behring Institute Mitteilungen, 1988, Issue:83 Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Northern; Bone Marrow Transplantation; Bus	1988
High-dose busulfan and cyclophosphamide with autologous bone marrow transplantation support in advanced malignancies in children: a phase II study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986, Volume: 4, Issue:12 Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Busulfan; C	1986
Phase I study of high-dose dimethylbusulfan followed by autologous bone marrow transplantation in patients with advanced malignancy. Cancer treatment reports, 1987, Volume: 71, Issue:1 Topics: Adolescent; Adult; Bone Marrow Transplantation; Busulfan; Child; Combined Modality Therapy; Drug Eva	1987
Use of donors sharing one genetic haplotype for bone marrow transplantation. The Tokai journal of experimental and clinical medicine, 1985, Volume: 10, Issue:2-3 Topics: Bone Marrow Transplantation; Busulfan; Cyclophosphamide; Cyclosporins; Dose-Response Relationship, I	1985
[Can cytostatic agents cause cancer?]. Nederlands tijdschrift voor geneeskunde, 1972, Aug-12, Volume: 116, Issue:33 Topics: Adult; Antineoplastic Agents; Busulfan; Epithelial Cells; Epithelium; Female; Humans; Leukemia, Myel	1972
Blood and neoplastic diseases. Rational approach to the chemotherapy of human malignant disease-II. British medical journal, 1974, Oct-26, Volume: 4, Issue:5938 Topics: Antineoplastic Agents; Brain Neoplasms; Busulfan; Cell Count; Cell Division; Cytarabine; Diffusion;	1974
[Complications in oncologic therapy]. Deutsche medizinische Wochenschrift (1946), 1974, Volume: 99, Issue:18 Topics: Acute Kidney Injury; Antineoplastic Agents; Bone Marrow Diseases; Busulfan; Cyclophosphamide; Humans	1974
[Chemotherapy of cancer. Hints for continuing medical education]. Zeitschrift fur arztliche Fortbildung, 1974, Feb-15, Volume: 68, Issue:4 Topics: Antineoplastic Agents; Busulfan; Chlorambucil; Cyclophosphamide; Cytarabine; Daunorubicin; Education	1974
[Secondary tumors in hemoblastoses during cytostatic treatment]. Medizinische Klinik, 1971, Oct-22, Volume: 66, Issue:43 Topics: Adrenal Gland Neoplasms; Aged; Antineoplastic Agents; Bronchial Neoplasms; Busulfan; Carcinoma; Chlo	1971
Cell proliferation and the differential response of normal and malignant tissues. Silvanus Thompson Memorial Lecture. The British journal of radiology, 1972, Volume: 45, Issue:531 Topics: Animals; Blood Vessels; Busulfan; Cell Survival; Cyclophosphamide; Cytarabine; Diffusion; Epithelial	1972
[Carcinogenic effects of anti neoplastic and immunosuppressive drugs]. Arzneimittel-Forschung, 1971, Volume: 21, Issue:4 Topics: Alkylating Agents; Animals; Antimetabolites; Busulfan; Cyclophosphamide; Neoplasms; Rats; Statistics	1971
Oncology: its scope and prospects. Proceedings of the Royal Society of Medicine, 1971, Volume: 64, Issue:3 Topics: Burkitt Lymphoma; Busulfan; Carcinogens; Choriocarcinoma; Climate; DNA Replication; Environment; Fem	1971
[Cancerogenicity of cytostatics]. Deutsche medizinische Wochenschrift (1946), 1971, Volume: 96, Issue:40 Topics: Animals; Antineoplastic Agents; Busulfan; Humans; Leukemia, Myeloid; Neoplasms; Neoplasms, Experimen	1971
[Chemotherapy of malignant tumors in the limbs]. Handchirurgie, 1969, Volume: 1, Issue:3 Topics: Antineoplastic Agents; Arm; Busulfan; Chemical Phenomena; Chemistry; Cyclophosphamide; Esters; Ethyl	1969
[Desired and undesirable effects of cytostatic therapy]. Medizinische Klinik, 1967, Oct-27, Volume: 62, Issue:43 Topics: Androgens; Anti-Bacterial Agents; Antineoplastic Agents; Busulfan; Chlorambucil; Cyclophosphamide; E	1967
[The role of the thrombocytes in the induction of intravascular coagulation]. Bibliotheca haematologica, 1969, Volume: 32 Topics: Animals; Blood Coagulation Disorders; Blood Platelets; Busulfan; Fibrin; Fibrinogen; Hemolysis; Inje	1969

busulfan and Benign Neoplasms